The objective of this trial is to assess the efficacy of reducing plasma low-density lipoprotein(LDL) cholesterol and safety in two different brand drugs, Roty F.C. Tablets 10mg and Crestor 10mg F.C. Tablets in hypercholesterolemia population.

Inclusion Criteria:

• Male or female aged 20 to 85;
• LDL - C between 130 mg/dL and 250 mg/dL;
• TG < 400 mg/dL;
• Who without use of any statin within 2 week prior to the trial;
• Informed consent given.

Exclusion Criteria:

• Known hypersensitivity or history of SAE with another HMG-CoA reductase inhibitor, in particular any history of myopathy;
• Active liver disease/severe hepatic impairment(Child-Pugh C,ALT2×ULN);
• Treatment with Cyclosporin or any disallowed drug;
• Patients with unstable angina pectoris;
• Pregnant, lactating women;
• Patients who have severe medical condition(s) that in the view of the Investigator prohibits participation in the trial.